This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocuphire Pharma (OCUP) delivered earnings and revenue surprises of -3.45% and 38.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of -8.26% and 65.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -100% and 4.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beauty Health (SKIN) delivered earnings and revenue surprises of 28.57% and 1.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
by Zacks Equity Research
Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
by Zacks Equity Research
Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
by Zacks Equity Research
Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
by Zacks Equity Research
Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
FDA Updates Labels of Esperion's (ESPR) Cholesterol-Lowering Drugs
by Zacks Equity Research
The label to Esperion's (ESPR) marketed drugs Nexletol and Nexlizet have been updated to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations.
Bears are Losing Control Over Ocuphire Pharma, Inc. (OCUP), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Ocuphire Pharma, Inc. (OCUP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent
by Zacks Equity Research
Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.
MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study
by Zacks Equity Research
MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expected in late 2023.
FTC Challenges Amgen's (AMGN) $28B Acquisition of Horizon
by Zacks Equity Research
Per the FTC, Amgen's (AMGN) acquisition of Horizon (HZNP) would entrench the monopoly positions for the latter's medications for thyroid eye disease and chronic refractory gout.
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
by Zacks Equity Research
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.
Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far
by Zacks Equity Research
Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.
Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases
by Zacks Equity Research
Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.
ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray
by Zacks Equity Research
ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions.
Sarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel
by Zacks Equity Research
The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.
ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why
by Zacks Equity Research
ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ovarian cancer. An encouraging initial sales uptake of its first marketed product, Elahere, also contribute to the surge.
Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates
by Zacks Equity Research
Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.
TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines
by Zacks Equity Research
TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow
by Zacks Equity Research
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.
Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y
by Zacks Equity Research
Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.